Department of Urology, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa, 903-0215, Japan.
Naha City Hospital, Naha, Okinawa, Japan.
BMC Res Notes. 2021 Jun 3;14(1):227. doi: 10.1186/s13104-021-05641-5.
To date, there are no useful markers for predicting the prognosis of metastatic hormone-sensitive prostate cancer (mHSPC). We evaluated the effect of early changes in prostate-specific antigen (PSA) levels after androgen deprivation therapy (ADT) on castration-resistant prostate cancer (CRPC) progression and overall survival (OS) in mHSPC patients.
In 71 primary mHSPC patients treated with ADT, the median times to CRPC and OS were 15 months and 92 months, respectively. In multivariate analysis, a Gleason score of ≥ 8 (p = 0.004), an extent of disease value (EOD) of ≥ 2 (p = 0.004), and a 3-month PSA level > 1% of the pretreatment level (p = 0.017) were independent predictors of shorter time to CRPC. The area under the receiver operating characteristic curve was feasible at 0.822. A 3-month PSA level > 1% of the pretreatment level was an independent predictor of OS (p = 0.004). Three factors were independent predictors of shorter time to CRPC. A 3-month PSA level > 1% of the pretreatment level correlated with a poor prognosis.
迄今为止，尚无有用的标志物可用于预测转移性激素敏感性前列腺癌（mHSPC）的预后。我们评估了去势治疗（ADT）后前列腺特异性抗原（PSA）水平的早期变化对 mHSPC 患者发生去势抵抗性前列腺癌（CRPC）进展和总生存期（OS）的影响。
在 71 例接受 ADT 治疗的原发性 mHSPC 患者中，CRPC 和 OS 的中位时间分别为 15 个月和 92 个月。多因素分析显示，Gleason 评分≥8（p=0.004）、疾病程度值（EOD）≥2（p=0.004）和 3 个月 PSA 水平高于治疗前水平的 1%（p=0.017）是 CRPC 发生时间更短的独立预测因素。受试者工作特征曲线下面积为 0.822。3 个月 PSA 水平高于治疗前水平是 OS 的独立预测因素（p=0.004）。有三个因素是 CRPC 发生时间更短的独立预测因素。3 个月 PSA 水平高于治疗前水平与预后不良相关。
